JP2025501755A5 - - Google Patents

Info

Publication number
JP2025501755A5
JP2025501755A5 JP2024538030A JP2024538030A JP2025501755A5 JP 2025501755 A5 JP2025501755 A5 JP 2025501755A5 JP 2024538030 A JP2024538030 A JP 2024538030A JP 2024538030 A JP2024538030 A JP 2024538030A JP 2025501755 A5 JP2025501755 A5 JP 2025501755A5
Authority
JP
Japan
Prior art keywords
aso
restricted
modification
use according
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538030A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501755A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/082380 external-priority patent/WO2023122800A1/en
Publication of JP2025501755A publication Critical patent/JP2025501755A/ja
Publication of JP2025501755A5 publication Critical patent/JP2025501755A5/ja
Pending legal-status Critical Current

Links

JP2024538030A 2021-12-23 2022-12-23 脆弱x関連障害に対する治療的処置 Pending JP2025501755A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163265989P 2021-12-23 2021-12-23
US63/265,989 2021-12-23
PCT/US2022/082380 WO2023122800A1 (en) 2021-12-23 2022-12-23 Therapeutic treatment for fragile x-associated disorder

Publications (2)

Publication Number Publication Date
JP2025501755A JP2025501755A (ja) 2025-01-23
JP2025501755A5 true JP2025501755A5 (cg-RX-API-DMAC10.html) 2026-01-06

Family

ID=85199427

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538030A Pending JP2025501755A (ja) 2021-12-23 2022-12-23 脆弱x関連障害に対する治療的処置

Country Status (9)

Country Link
EP (1) EP4453212A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025501755A (cg-RX-API-DMAC10.html)
KR (1) KR20240133725A (cg-RX-API-DMAC10.html)
CN (1) CN118679257A (cg-RX-API-DMAC10.html)
AU (1) AU2022417615A1 (cg-RX-API-DMAC10.html)
CA (1) CA3240593A1 (cg-RX-API-DMAC10.html)
IL (1) IL313726A (cg-RX-API-DMAC10.html)
MX (1) MX2024007908A (cg-RX-API-DMAC10.html)
WO (1) WO2023122800A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240947A1 (en) * 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
WO1998010090A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
ES2756326T3 (es) * 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulación de la expresión de distrofia miotónica-proteína quinasa (DMPK)
WO2012174610A1 (en) * 2011-06-24 2012-12-27 Murdoch Childrens Research Institute Treatment and diagnosis of epigenetic disorders and conditions
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4397759A3 (en) 2012-10-23 2024-10-09 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
KR102955556B1 (ko) 2012-12-12 2026-04-22 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
MX380562B (es) 2012-12-12 2025-03-12 Broad Inst Inc Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
CA2921457A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Heterochromatin forming non-coding rnas
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
GB2574243A (en) * 2018-05-31 2019-12-04 The Govening Council Of The Univ Of Toronto Adeno-associated viral vector-mediated gene therapy for treating fragile X-associated disorders
MX2021010255A (es) * 2019-02-26 2021-12-15 Nogra Pharma Ltd Oligonucleotidos que interferen con proteina de retraso mental de x fragil y metodos para usar los mismos.
EP3966326A1 (en) * 2019-05-07 2022-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Fmrp and cancer treatment
CN113151406B (zh) * 2021-03-25 2022-06-21 深圳会众生物技术有限公司 Fmr1基因cgg重复数及甲基化检测试剂盒和检测方法

Similar Documents

Publication Publication Date Title
JP7442574B2 (ja) Lpaの遺伝子発現の阻害のための組成物及び方法
AU2004221760B2 (en) Short interfering RNA (siRNA) analogues
EP1937312B1 (en) Chimeric oligomeric compounds for modulation of splicing
EP3484524B1 (en) Compounds and methods for modulation of smn2
CN116157520A (zh) 用于基因组编辑的组合物和方法
WO2020165077A1 (en) Antisense oligonucleotides for nucleic acid editing
JP2021533804A5 (cg-RX-API-DMAC10.html)
JP2016528897A (ja) Rnaを調節するための組成物および方法
TW201639962A (zh) Rna干擾劑
TW201702378A (zh) 反義誘導之酸性α-葡萄苷酶中的外顯子2包含
FI4220360T3 (fi) Oligonukleotideja paternaalisen ube3a:n ilmentämiseksi
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
CA2921457A1 (en) Heterochromatin forming non-coding rnas
CA3118167A1 (en) Bispecific antisense oligonucleotides for dystrophin exon skipping
JP2024516183A5 (cg-RX-API-DMAC10.html)
RU2020125769A (ru) Олигонуклеотиды для модуляции экспрессии tmem106b
WO2023034870A2 (en) Compounds and methods for reducing dmpk expression
US20260062703A1 (en) Delivery of RNA Therapeutics Using Circular Prodrug Nucleic Acids
TW202329983A (zh) Rna編輯
TW202333795A (zh) 具有一或多個無鹼基單元之反義寡核苷酸
JP2024536132A5 (cg-RX-API-DMAC10.html)
KR101783444B1 (ko) miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법
CN114867856A (zh) Saraf抑制剂用于治疗乙型肝炎病毒感染的用途
US6238917B1 (en) Asymmetric hammerhead ribozymes
EP4332221A1 (en) Threose nucleic acid antisense oligonucleotides and methods thereof